Patients on Pfizer's anti-coronary drug report: "Relief after two days"
Everyone who took the drug reported significant relief of symptoms and none of them came to the hospital.
"It can certainly alleviate the load and reduce the risk of getting a serious illness," HMOs say.
The responsiveness, however, is not impressive.
Of the 638 patients found eligible for admission, 138 refused
Meirav Cohen
10/01/2022
Monday, 10 January 2022, 08:00
Share on Facebook
Share on WhatsApp
Share on Twitter
Share on Email
Share on general
Comments
Comments
In the video: First delivery of Pfizer medicine to the corona virus (Walla system!)
One week after Pfizer's drug for the treatment of corona arrived in Israel, the impression is that the response to taking it is not high.
In contrast, the results reported by those who took it are impressive.
Of the 638 patients whose suitability for the drug was tested, 138 refused to receive it, some out of fear of discontinuing their regular medication.
Among those who refuse, there are also those who have not been vaccinated at all.
The largest number of refusals was recorded in the Maccabi Health Fund.
Of the 198 patients found eligible for the drug, 119 refused.
At the United Health Insurance Fund, about a third of the patients refused.
The National Health Fund had a good response, and only a few refused out of 70 patients who were found suitable.
More on Walla!
Israelis who fear being infected are in no hurry to be tested at home: "I will not put myself in solitary confinement voluntarily"
To the full article
More on Walla!
Lieberman's explanation to business owners: "No closure - no grant for every citizen"
Research: The fourth vaccine is safe to use, its side effects are known
A unique method was developed in Israel for acne problems - over 50,000 people died from the wounds
The important statistic regarding the drug is that everyone who took it reported significant relief of symptoms. None of these patients came to the hospital, although all beneficiaries are defined as those at risk. Dan Kinner, 76, a member of Meuhedet, said that "I was told by the HMO that I was entitled and that medicine would help me not to deteriorate into a serious illness. After only two days I began to feel relief from hoarseness. I must say that the HMO was very active and I felt taken care of."
Elisheva from Jaffa also belongs to a risk group due to the breast cancer she suffered from and the asthma she suffers from. "From the moment the doctor recommended the medicine to me, it was three hours before she came to my house," she said excitedly. According to her, in the first days she felt headaches and joint pain, and her senses of taste and smell were lost. "After five days the pain is gone, and slowly the senses return," she says. "I do not know what would have happened without the drug. Lucky I do not have to find out."
Pfizer's drugs at Teva's logistics center (Photo: Official website, Teva-Sla)
Dr. Maya Rosen, Medical Director of the Central District of Clalit Health Fund, explained that Pfizer's drug has a higher response than Regeneron, which is given by infusion. "The feeling that the patient can take the drug himself helps them respond positively.
Among those who refuse, some are afraid, and a minority of them do not believe in the health system and also refused to be vaccinated.
I do not think the drug will completely change the situation because it can not reduce the infection and prevent an outbreak, but it can certainly alleviate the burden in the hospital, and most importantly - reduce the risk of developing a serious disease among at-risk populations.
We need a lot more pills to see a broad impact, but so far there has not been a single hospitalization, and that is a great figure. "
At the same time, this morning (Sunday), the first shipment of the drug to Corona "Molnofiravir" from MSD landed, which includes 60,000 pills.
This drug will be in use this week.
According to the data, molenophyrovirus is 90% effective in preventing mortality, and 30% in preventing serious illness and hospitalizations.
The drug is supposed to be taken five days from the date of exposure, and it maintains its effectiveness against the omicron variant and is intended for patients in corona in a mild-moderate condition.
news
Corona
Tags
Corona virus
Pfizer
